Table 1.

C1q and MBL inhibition in sera from immunocompromised patients.

Diagnosis	Treatment	IgG/IgM/IgA (g/L)	Bound IgG/IgM	C3b after MBL inhibition (%)	C3b after C1q inhibition (%)
IgA deficiency	No	16.2/0.6/<0.05	+++/+++	↑3	↓67
X-linked agammaglobulinemia	IgG therapy	10.3/<0.05/<0.05	++/−	↓61	↓18
Common variable immunodeficiency	No	2.6/<0.05/<0.05	+/+	↓75	↓7

A. fumigatus (1 × 10⁷ conidia/ml) was incubated with sera from three patients with different immune disorders. Bound IgG and IgM were compared and rated relative to an NHS pool: >100%: +++; 50–100%: ++; <50%: +; 0%: −. The effect of C1q and MBL inhibition was evaluated based on the C3b deposition. The results show the mean% reduction in C3b deposition caused by the inhibitor [(1 − C3b with inhibitor/C3b with mock-inhibitor)%]. Serum levels of IgG, IgM, and IgA were obtained from the clinical records, and calculations of bound IgG/IgM and C3b were based on flow cytometric mean fluorescence intensity values. Inhibition experiments represent the means of three independent experiments. Downward-pointing arrows indicate a C3b reduction and upward-pointing arrows a C3b increase.